Why Hepatitis E Seroprevalence Numbers Are Surprisingly Unstable
When health authorities attempt to track the spread of infectious diseases, they rely on what should be concrete numbers: seroprevalence rates that indicate what percentage of a population has been exposed to a pathogen. But what happens when these numbers keep changing? This isn't a mathematical error—it's a fascinating scientific puzzle playing out in real-time with the hepatitis E virus (HEV), an emerging pathogen that's challenging our understanding of viral epidemiology.
HEV has long been recognized as a major cause of acute viral hepatitis worldwide, with an estimated 20 million infections occurring annually 9 . Traditionally associated with waterborne outbreaks in developing countries, we now understand HEV as a global pathogen with multiple transmission routes—from contaminated water and undercooked meat to blood transfusions and organ transplants 5 6 .
As researchers race to understand its true impact, they're confronting a troubling reality: depending on how you test for it, HEV seroprevalence rates can vary dramatically, sometimes by shocking margins of over 40% in the same population . This variability has profound implications for public health policy, blood safety protocols, and our fundamental understanding of this neglected pathogen.
20 Million
Estimated annual HEV infections worldwide
Up to 20%
Mortality rate in pregnant women
Seroprevalence represents the proportion of a population that carries antibodies against a specific pathogen, indicating past or current infection. For public health officials, these numbers are crucial for:
Accurate seroprevalence data helps allocate healthcare resources effectively and understand the true impact of HEV across populations.
Seroprevalence studies reveal which groups are most vulnerable, enabling targeted prevention and intervention strategies.
Reliable data guides decisions on whether to screen blood donations for HEV, protecting transfusion recipients.
Consistent measurement over time reveals how HEV spreads and evolves across different regions and populations.
For HEV, accurate seroprevalence data is particularly important because while the infection is typically self-limiting in healthy individuals, it can cause severe or chronic disease in immunocompromised patients, including organ transplant recipients, people living with HIV, and those undergoing chemotherapy 6 9 . Furthermore, HEV infection in pregnant women can lead to maternal mortality rates up to 20% 5 , making accurate surveillance a life-or-death matter.
The central problem in HEV seroprevalence studies lies in the lack of standardized testing methods. Unlike some viruses where antibody tests are well-harmonized, HEV testing employs various platforms that produce strikingly different results:
From different manufacturers using various recombinant antigens with varying sensitivity and specificity.
Offer automation but different detection thresholds and performance characteristics.
Serve as reference standards but aren't practical for large-scale epidemiological studies.
This methodological variability means that a single blood sample might test positive on one platform but negative on another. A 2024 study comparing four HEV antibody assays found that while IgM sensitivity in the acute phase was 100% across all techniques, sensitivity during the convalescence phase ranged from 83.14% to 96.74% depending on the test used 2 . Similarly, IgG specificity reached 97.17% for some assays but only 88.68% for others 2 .
| Assay Type | IgM Sensitivity (Convalescence) | IgG Specificity | Best Use Case |
|---|---|---|---|
| LIAISON® MUREX | 96.74% | 97.17% | Acute infection detection |
| VIRCLIA® | 83.14% | 88.68% | High-specificity settings |
| WANTAI ELISA | 84.78% | >99% 4 | Population prevalence studies |
| VIDAS® | 88.04% | Not reported | Routine clinical settings |
| Region/Country | Reported Seroprevalence | Population Studied | Key Factors |
|---|---|---|---|
| Egypt | Up to 84.3% 8 | General population | Endemic region, waterborne transmission |
| Serbia | 15% 7 | Blood donors | Pig farming, traditional consumption |
| Iran | 7.4% 3 | General population | Age, traditional phlebotomy |
| Saudi Arabia | 22.1% 8 | Blood donors | Occupational exposure variations |
| Central Vietnam | 26-36% 4 | Chronic liver disease patients | Zoonotic transmission |
| Nepal | 43.5% 9 | HIV-positive individuals | Immunocompromised status |
| Turkey | 26.25% 5 | Hemodialysis patients | Medical exposure, age |
| India | 1.41% 1 | Blood donors (IgM) | Recent infection rate |
To understand precisely how testing methodologies impact seroprevalence figures, consider a compelling study conducted in Italy's Greater Romagna area . Researchers designed an elegant experiment: instead of testing different populations with different methods, they would test the same 500 blood donors using three different commercial ELISA tests:
Their routine test for HEV seroprevalence studies
A widely used commercial test with reported high specificity
Another commonly used commercial ELISA test
All samples were processed following manufacturer instructions, and any positive or borderline results were confirmed with an immunoblotting assay—considered a more definitive reference method. This design allowed for direct comparison without population variability confounding the results.
The findings revealed dramatic differences in seroprevalence depending solely on the test used:
| Testing Method | Initial Positive Results | Confirmed Positive After Immunoblot | Final Seroprevalence |
|---|---|---|---|
| DIA.PRO | 22/500 (4.4%) | 19/500 | 3.8% |
| Wantai | 17/500 (3.4%) | 14/500 | 2.8% |
| Euroimmun | 11/500 (2.2%) | 8/500 | 1.6% |
The implications were clear: the same population appeared to have dramatically different exposure rates to HEV depending on which test was used. A public health official using the DIA.PRO assay would report more than double the seroprevalence compared to a colleague using the Euroimmun assay on the same population .
Perhaps most surprisingly, when researchers compared their results to a previous study conducted in a geographically close area that had reported an astonishing 49% seroprevalence among blood donors, it highlighted how methodological differences could produce wildly varying epidemiological pictures .
Certain populations consistently show elevated HEV exposure rates, revealing important patterns in transmission dynamics:
Understanding HEV diagnostics requires familiarity with the essential research tools that scientists use to detect and study the virus:
Available from multiple manufacturers (Wantai, Dia.Pro, Euroimmun), these kits form the backbone of HEV seroprevalence studies. They differ in the specific antigens used, detection methods, and interpretation thresholds .
Considered confirmation tests, these can distinguish between IgM and IgG antibodies and provide more specific results by displaying multiple antigen bands. The RecomLine HEV IgG/IgM (Mikrogen) is a commonly used immunoblot .
Automated systems like LIAISON® XL and VIRCLIA® offer higher throughput and standardization for clinical laboratories 2 .
Virus-like particles produced through baculovirus expression systems show promise as antigens in serological assays, potentially offering improved sensitivity 8 .
The variability in HEV seroprevalence data isn't merely an academic concern—it has real-world consequences for clinical practice and public health policy. Without reliable numbers, health authorities cannot make evidence-based decisions about screening blood donations, allocating resources, or measuring intervention effectiveness.
The inconsistencies also highlight critical gaps in our fundamental understanding of HEV biology:
How long do HEV antibodies persist after infection?
Do different genotypes trigger different antibody responses?
How does immune status affect antibody kinetics?
Fortunately, the scientific community is responding to these challenges with calls for standardized reference materials, multicenter method comparisons, and harmonized testing algorithms . Some researchers suggest that the solution lies in adopting a dual-algorithm approach combining the most sensitive tests for screening with the most specific tests for confirmation.
As research continues, one thing has become clear: our understanding of HEV's global impact is still evolving. The shifting seroprevalence numbers don't mean we can't trust the science—rather, they reflect the sophisticated detective work underway to better understand this complex pathogen. Each recalibration of seroprevalence data represents not a step backward, but a refinement of our knowledge moving us closer to effective control strategies for this neglected but important viral pathogen.
The journey to unravel HEV's true prevalence continues, but one message is already clear: in the complex world of infectious disease epidemiology, sometimes the most honest answer is "it depends on how you measure."